p16, cyclin D1 and Rb expression in colorectal carcinomas: Correlations with clinico-pathological parameters and prognosis

Molecular Medicine Reports

Volumn 1, Issue 1, 2008, Pages 27-32

  Von Stockmar Von Wangenheim, Caroline A S ^a   Mönig, Stefan P ^a   Schneider, Paul M ^a   Landsberg, Stephanie ^a   Drebber, Uta ^a   Hölscher, Arnulf H ^a   Dienes, Hans P ^a   Baldus, Stephan E ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Colorectal carcinoma; Cyclin D1; Monoclonal antibody; p16; Prognosis; Rb

Indexed keywords

CYCLIN D1; MONOCLONAL ANTIBODY; PROTEIN P16; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CECUM; CELL CYCLE REGULATION; CELL NUCLEUS; COLORECTAL CARCINOMA; CORRELATIONAL STUDY; CYTOPLASM; DISEASE MARKER; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION;

EID: 69249141508     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994. (Pubitemid 24363801)
2. Reed SI: Control of the G1/S transition. Cancer Surv 29: 7-23, 1997.
3. Weinstein IB and Zhou P: Cell cycle control and gene defects and human cancer. In: Encyclopedia of Cancer. Bertino JR (ed). Academic Press, New York, pp256-267, 1997.
4. Serrano M, Gomez-Lahoz E, De Pinho RA, Beach D and Bar-Sagi D: Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267: 249-252, 1995.
5. Medema RH, Herrera RE, Lam F and Weinberg RA: Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92: 6289-6293, 1995.
6. Koh J, Enders GH, Dynlacht BD and Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510, 1995.
7. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y and Enders GH: P16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119: 929-942, 2000. (Pubitemid 30777913)
8. Geradts J and Wilson PA: High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 149: 15-20, 1996. (Pubitemid 26230973)
9. Betticher DC, White GR, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N and Heighway J: G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 74: 556-562, 1997. (Pubitemid 27486516)
10. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J and Kaye FJ: Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87: 1870-1875, 1995.
11. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT and Cheng AL: Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 57: 149-156, 1999.
12. Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K and Watanabe G: Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 10: 935-938, 2003.
13. Guan RJ, Fu Y, Holt PR and Pardee AB: Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 116: 1063-1071, 1999. (Pubitemid 29203016)
14. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G and Peinado MA: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19: 299-304, 2001. (Pubitemid 32112840)
15. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D and Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817, 1994.
16. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T and Thatcher N: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73: 294-300, 1996. (Pubitemid 26047506)
17. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, Qiu SL and Yang CS: Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 59: 514-519, 1994. (Pubitemid 24357277)
18. Dirks PB, Hubbard SL, Murakami M and Rutka JT: Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol 56: 291-300, 1997. (Pubitemid 27461170)
19. Izawa H, Yamamoto H, Ikeda M, Fukunaga H, Yasui M, Ikenaga M, Sekimoto M, Monden T, Matsuura N and Monden M: Analysis of cyclin D1 and CDK expression in colonic polyps containing neoplastic foci: a study of proteins extracted from paraffin sections. Oncol Rep 9: 1313-1318, 2002.
20. Holland TA, Elder J, McCloud JM, Hall C, Deakin M, Fryer AA, Elder JB and Hoban PR: Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patient survival. Int J Cancer 95: 302-306, 2001. (Pubitemid 32847040)
21. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, Nakata B, Nishiguchi Y, Ikehara T, Okuno M and Sowa M: Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74: 310-315, 1997. (Pubitemid 27321801)
22. Bartkova J, Lukas J, Strauss M and Bartek J: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 58: 568-573, 1994. (Pubitemid 24268101)
23. Wong NA, Morris RG, McCondochie A, Bader S, Jodrell DI and Harrison DJ: Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol 197: 128-135, 2002.
24. McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL and Murray GI: Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196: 386-393, 2002. (Pubitemid 34262849)
25. Lohmann DR, Brandt B, Hopping W, Passarge E and Horsthemke B: The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. Am J Hum Genet 58: 940-949, 1996. (Pubitemid 26115165)
26. Yokota J, Akiyama T, Fung YK, et al: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475, 1988. (Pubitemid 18265202)
27. T'Ang A, Varley JM, Chakraborty S, Murphree AL and Fung YK: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263-266, 1988. (Pubitemid 18253486)
28. Backus HH, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM and Peters GJ: Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55: 206-211, 2002. (Pubitemid 34250907)
29. Kohn GJ, Schwartz HJ, Ruebner BH, Wong AJ and Lawson MJ: Colonic retinoblastoma protein and proliferation in cancer and non-cancer patients. J Gastroenterol Hepatol 12: 198-203, 1997.
30. Bukholm IK and Nesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 436: 224-228, 2000.
31. Palmqvist R, Rutegard JN, Bozoky B, Landberg G and Stenling R: Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol 157: 1947-1953, 2000.
32. McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI and McLeod HL: Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 6: 1113-1118, 2000. (Pubitemid 30159374)
33. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S and El-Serafi M: Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 4: 22, 2004. (Pubitemid 39637354)
34. Schwandner O, Bruch HP and Broll R: p21, p27, cyclin D1 and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorectal Dis 17: 11-19, 2002.
35. Balcerczak E, Pasz-Walczak G, Kumor P, Panczyk M, Kordek R, Wierzbicki R and Mirowski M: Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur J Surg Oncol 31: 721-726, 2005. (Pubitemid 41194648)
36. Norrie MW, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW and Ward RL: Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 84: 143-150, 2003.
37. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT and Chaubert P: Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 81: 217-229, 2001. (Pubitemid 32176386)
38. Maekawa M, Sugano K, Ushiama M, Fukayama N, Nomoto K, Kashiwabara H, Fujita S and Kakizoe T: Heterogeneity of DNA methylation status analyzed by bisulfite-PCR-SSCP and correlation with clinico-pathological characteristics in colorectal cancer. Clin Chem Lab Med 39: 121-128, 2001. (Pubitemid 32318475)
39. Shannon BA and Iacopetta BJ: Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett 167: 91-97, 2001.
40. Zhao P, Hu YC and Talbot IC: Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9: 2202-2206, 2003. (Pubitemid 37321445)
41. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, Ohue M, Sekimoto M, Monden T, Matsuura N and Monden M: Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 26: 1217-1226, 2005.
42. Tada T, Watanabe T, Kazama S, Kanazawa T, Hata K, Komuro Y and Nagawa H: Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology 50: 1756-1760, 2003. (Pubitemid 37467927)
43. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S and Hatakeyama K: Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 35: 1189-1195, 2004. (Pubitemid 39361641)
44. Bondi J, Bukholm G, Nesland JM and Bukholm IR: Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112: 49-56, 2004. (Pubitemid 38297167)
45. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A and Bukholm IR: Expression and gene amplification of primary (A, B1, D1, D3 and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 58: 509-514, 2005. (Pubitemid 40646872)
46. Palmqvist R, Stenling R, Oberg A and Landberg G: Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 34: 1575-1581, 1998. (Pubitemid 28446340)
47. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM and Peters GJ: Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12: 779-785, 2001. (Pubitemid 32655086)